FNP: COPD & Asthma

GINA guidelines no longer support SABA-only treatment for adults because it increases the risk of severe exacerbations. The preferred Step 1 and 2 treatment track is as-needed low-dose ICS-formoterol to provide both symptom relief and anti-inflammatory control. Option B is an alternative track but is not the preferred primary approach for adults. Option C is outdated and actively discouraged due to safety concerns. Option D offers an alternative controller but is less effective and not the preferred initial stepwise approach for this patient.

A reading of 280 L/min is 46% of the patient's personal best, placing him firmly in the Red Zone. Because he remains in this zone despite initial rescue therapy and is exhibiting signs of respiratory distress, he is having a severe exacerbation. Immediate administration of systemic steroids and transfer to a higher level of care are required. Option A and Option B are incorrect because adjusting chronic maintenance medications does not address the acute, life-threatening bronchospasm occurring right now. Option D is dangerous; observing a patient in severe distress without escalating acute treatment can lead to respiratory failure.

The patient's accessory muscle use and inability to speak in full sentences indicate a severe asthma exacerbation. Current guidelines recommend the immediate use of a short-acting beta-agonist combined with a short-acting muscarinic antagonist, such as albuterol and ipratropium, along with systemic corticosteroids to maximize bronchodilation and reduce inflammation. Using albuterol alone is sufficient for mild-to-moderate exacerbations but suboptimal for severe cases. Intravenous magnesium sulfate is reserved for life-threatening exacerbations or those that remain unresponsive to initial intensive bronchodilator therapy; it is not the first-line step before administering systemic steroids.

This patient is experiencing a severe COPD exacerbation with purulent sputum, indicating the need for antibiotic therapy. His recent hospitalization and frequent use of broad-spectrum antibiotics place him at a high risk for Pseudomonas aeruginosa infection. In this scenario, an antipseudomonal fluoroquinolone like oral levofloxacin or ciprofloxacin is the preferred choice. Options A, B, and D (azithromycin, doxycycline, and amoxicillin) are excellent choices for uncomplicated exacerbations but lack reliable coverage against Pseudomonas, making them inappropriate for a patient presenting with these specific high-risk clinical features.

While occupational exposures in agricultural settings are a well-documented risk factor for chronic respiratory disease, a post-bronchodilator FEV1/FVC ratio of 0.75 definitively rules out COPD, which strictly requires a ratio below 0.70. Option A is incorrect because COPD cannot be diagnosed without objective spirometric evidence of irreversible airflow obstruction, regardless of the patient's symptom presentation. Option B is inappropriate as there is absolutely no evidence of reversible airway disease or asthma presented in this scenario. Option D is incorrect because methacholine challenges are typically reserved to diagnose asthma in patients with normal baseline spirometry but intermittent symptoms, whereas this patient has a persistent chronic cough that requires investigating other common etiologies such as gastroesophageal reflux, postnasal drip, or occupational hypersensitivity pneumonitis.